- While the post-operative pain management market is anticipated to grow, the U.S. is looking for alternatives to traditional opioid administration
- Endonovo has alternative technologies that allow for effective pain and swelling management, bringing down the need for the administration of opioids
- Endonovo announced the rollout of its therapeutic device in hospitals and pain management centers across the U.S.; it’s planning to be in the evaluation stage with 600 hospitals over the course of 18 months
The global post-operative pain management market is anticipated to grow at a CAGR of 5.4 percent through 2023, with an increasing number of surgeries worldwide and a growing prevalence of different diseases as major factors for the growth of the market, according to a Market Research Future report (http://ibn.fm/iyZIR). An increasing aging population around the globe will also has a considerable impact on the growth of the market, the report underlines.
Apart from expanding, this market is also rapidly evolving. Researchers are currently working on effective pain management solutions with minimal side effects, amid growing concerns over the high number of pain management drug overdoses. Some reports even suggest that the opioid crisis in the U.S. is the result of inappropriate pain management after surgery (http://ibn.fm/WZCks).
The federal government has provided more than $2.4 billion in grants since 2017 to stimulate the development of alternatives for pain management in an attempt to reduce the scope of opioid addiction.
Endonovo Therapeutics Inc. (OTCQB: ENDV) is delivering a safe and reliable alternative to opioid medications for the management of pain.
Endonovo offers safe, wearable and non-invasive medical devices that deliver the company’s proprietary Electroceutical(TM) Therapy. The Endonovo SofPulse(R) device targets inflammatory conditions in both the organs and the peripheral tissues. Clinical research suggests that it can speed up the recovery process and reduce the need for administration of potentially addictive opioids.
Peer-reviewed clinical research shows that patients who are offered targeted pulsed electromagnetic field therapy (the patented therapeutic mode employed by SofPulse) experience reduced post-surgical pain. The need for the administration of narcotics is reduced 2.2 times and the patients benefit from improved wound healing, reduced inflammation and edema.
SofPulse was recently rolled out in hospitals, nursing centers and wound care centers throughout the U.S. as an effective post-surgical opioid alternative. As per an official Endonovo announcement, the company plans to be in the evaluation stage with 600 hospitals within the coming 18 months (http://ibn.fm/7L5G6). In addition, Endonovo will distribute SofPulse therapy devices to Veterans Administration facilities and Department of Defense health care facilities.
“The public is demanding change in pain management strategies, especially when it comes to opioid administration”, Endonovo CEO Alan Collier said in a news release. “Very few alternatives exist at the time being, which allows SofPulse to position itself as a natural and safe alternative.”
Endonovo’s SofPulse has U.S. Federal Drug Administration (FDA) clearance for the treatment of post-surgical pain and edema. SofPulse is also CE-marked in Europe for the promotion of wound health and the palliative treatment of post-surgical pain and edema.
For more information, visit the company’s website at www.Endonovo.com
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.